Core Viewpoint - The company, Edan Instruments, forecasts a net profit attributable to shareholders of 284 million to 332 million yuan for 2025, representing a year-on-year growth of 75% to 105% [1] Group 1: Financial Performance - The company expects steady growth in overall revenue for 2025, particularly in international markets, which are projected to maintain double-digit growth [1] - Non-recurring gains and losses are anticipated to impact net profit by approximately 14 million yuan, mainly from government subsidies, which is a decrease of around 4 million yuan compared to the previous year [1] Group 2: Business Strategy - The company continues to focus on its development strategy of "innovation, platform-based, and internationalization," enhancing its global business layout and service capabilities in overseas markets [1] - Edan Instruments is accelerating new product development and optimizing its marketing system while advancing its overseas manufacturing strategy [2] - The company has been collaborating with the Gates Foundation, with progress on handheld ultrasound devices reaching clinical validation and confirmation stages [2] Group 3: Operational Developments - A new facility in the U.S. covering 1,940 square meters has been added to enhance the company's business layout in North America and improve supply chain resilience [2] - The new facility has received comprehensive certifications, including MDSAP certification and the California FDB medical device production license [2] - The company plans to flexibly arrange domestic and overseas production capacity based on order demand after the new U.S. facility is operational, which is expected to enhance profitability in the long term [3]

Core Viewpoint - The company, Libang Instruments, forecasts a significant increase in net profit for the year 2025, expecting a rise of over 50% compared to the previous year [2]. Financial Performance - The net profit attributable to shareholders for the current reporting period is projected to be 28,369.15 million, representing a 75% increase compared to the same period last year, which was 16,210.94 million [3]. - The net profit after deducting non-recurring gains and losses is expected to be 27,294.31 million, reflecting a 90% increase from the previous year's 14,365.43 million [3]. Reasons for Performance Changes - The company has been focusing on an "innovative, platform-based, and international" development strategy, leading to steady growth in overall revenue, particularly in international markets, which have shown double-digit growth, especially in patient monitoring and ultrasound imaging [4]. - The company has improved its operational management and reduced marketing and R&D expenses effectively, aligning with its goal of enhancing quality and efficiency [4]. - Non-recurring gains and losses are expected to impact net profit by approximately 14 million, primarily from government subsidies, which have decreased by around 4 million compared to the previous year [4].

Core Viewpoint - The company, Lifesense Instruments (300206.SZ), expects a significant increase in net profit for 2025, projecting a growth of 75.00% to 105.00% compared to the previous year, driven by its strategic focus on innovation, platform development, and internationalization [1] Group 1: Financial Projections - The estimated net profit attributable to shareholders for 2025 is between 283.69 million and 332.32 million yuan, with a year-on-year growth of 75.00% to 105.00% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 272.94 million and 316.04 million yuan, reflecting a growth of 90.00% to 120.00% year-on-year [1] Group 2: Strategic Initiatives - The company continues to implement its development strategy focused on "innovation, platform-based, and internationalization," enhancing its global business layout and service capabilities in overseas markets [1] - The company is advancing its overseas manufacturing strategy and optimizing its marketing system, with a notable double-digit growth in international markets, particularly in patient monitoring and ultrasound imaging businesses [1] Group 3: Operational Efficiency - The company has focused on improving operational management and has effectively reduced marketing and R&D expenses while aiming for quality enhancement and efficiency [1] - The impact of non-recurring gains and losses on net profit is expected to be around 14 million yuan, primarily from government subsidies, which is a decrease of approximately 4 million yuan compared to the previous year [1]